The Institute for Clinical and Economic Review (ICER) has published its annual report on "unsupported" price increases for ...

The BBC's probe into Diary of a CEO has followed an increase in emphasis on health topics by Bartlett that, according to the ...

Editas ended the third quarter with cash reserves of around $256 million, down from $318 million three months earlier. It ...

Investors seemed to panic after the announcement, with a sell-off driving Keros' share price down 73%, reversing strong gains ...

While 2025 remains an unknown quantity, it’s clear that fundraisers and investors see the value in visiting London in ...

Private equity group Carlyle has joined forces with other investors on a €900 million-plus recapitalisation of UK drugmaker ...

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

A digital health application (DiGA) has been shown to relieve the distress that patients can experience when managing diabetes, which can compromise their care, in a randomised clinical trial.

In today’s fast-paced world, threats can evolve quickly and without warning. As the pharmaceutical industry has operations and supply chains spanning the globe, companies are vulnerable to ...

A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA, shortly after it showed preliminary signs of efficacy in a phase 1 trial.

With 2024 well under way, influential conferences in London have given a barometer reading on the conditions in the European biopharma market, reports Richard Staines. The Anglonordic Life Science ...